Market Research Industry Reports

Johnson and Johnson (JNJ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, womens health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 12
List of Figures 19
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 25
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27
Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 59
Asset Purchase 59
Janssen Pharma Acquires CERC-501 from Cerecor 59
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 60
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 61
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 62
Venture Financing 63
Evolve BioSystems Raises USD40 Million in Series C Financing 63
Syndesi Therapeutics Raises USD21 Million in Series A Financing 65
On Target Labs Raises USD40 Million in Series B Financing 67
BeneVir Biopharm Raises USD2 Million in Venture Financing 68
Fusion Pharma Raises Additional USD17 Million in Series A Financing 69
XW Labs Raises USD17.5 Million in Series B Financing 71
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 72
E-scape Bio Raises Additional USD8 Million in Series A Financing 73
DayTwo Secures USD12 Million in Series A Funding 74
DayTwo Raises USD12 Million in Series A Financing 75
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 76
Biomx Raises USD24 Million in Series A Venture Financing 77
Pulmocide Raises USD30.4 Million in Series B Financing 79
Fusion Pharma Raises USD19 Million in Series A Financing 81
SuperX Raises USD11 Million in Series A Financing 82
Caelus Health Raises USD2.7 Million in Series A Financing 83
ApoGen Biotech Raises USD7 Million in Series A Financing 84
ReVision Optics Raises USD32 Million in Venture Financing 85
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 87
BeneVir Biopharm Raises USD3 Million in Venture Financing 88
V-Wave Raises USD28 Million in Venture Financing 89
Lodo Therapeutics Raises USD17 Million in Series A Financing 90
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 92
Petra Pharma Raises USD48 Million in Series A Financing 93
Protekt Therapeutics Raises More Than USD2 Million in Financing 95
Navitor Pharma Raises USD33 Million in Series B Financing 96
First Aid Shot Therapy Raises USD24 Million in Series C Financing 98
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 99
Asceneuron Raises USD30.6 Million in Series A Financing 100
Merus Raises USD46.4 Million in First Tranche of Series C Financing 102
E-scape Bio Raises USD55 Million in Series A Financing 104
Alligator Bioscience to Raise Funds through Venture Financing 105
Protagonist Therapeutics Raises USD40 Million in Series C Financing 106
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 108
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 110
BeneVir Biopharm Raises Funds through Series A Financing 111
Tetra Discovery Raises Funds through Venture Financing 112
XW Labs Raises USD5.5 Million in Series A Financing 113
Inivata Raises USD6.5 Million in Venture Financing 114
Inviata Raises USD6.5 Million in Venture Financing 115
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 116
Ascelegen Therapeutics Raises Funds through Venture Financing 117
Padlock Therapeutics Raises Funds through Series A Financing 118
Navitor Pharma Raises USD24 Million in Series A Financing 119
Aduro BioTech Raises USD55 Million in Series C Financing 121
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 122
Assembly Pharma Raises Funds Through Seed Financing 123
Alios BioPharma Raises US$41 Million In Series B Venture Financing 124
Covagen Raises US$50.3 Million In Series B Financing 125
Novira Therapeutics Raises US$28 Million In Series A Financing 127
SutroVax Raises Funds Through Initial Financing Round 129
TopiVert Raises USD28 Million in Venture Financing 130
TopiVert Raises US$7.4 Million In Venture Financing 131
Pulmocide Raises US$27.4 Million In Series A Financing 133
Biocartis Raises US$40.5 Million In Series E Financing 135
Merus Raises US$42 Million In Extended Series B Financing 137
Rodin Therapeutics Raises Funds Through Seed Financing 139
Vedanta Biosciences Raises Funds Through Venture Financing 140
XO1 Raises USD11 Million in Venture Financing 141
X01 Raises US$11 Million In Series A Financing 142
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 143
Novira Therapeutics Secures USD25 Million in Venture Funding 144
Aquinox Pharma Raises US$18 Million In Series C Financing 145
Biocartis Raises US$44.7 Million In Series D Financing 146
Genocea Biosciences Raises US$30 Million In Series C Financing 148
Aragon Pharma Raises US$50 Million In Series D Financing 150
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 151
Celladon Raises Additional US$10 Million In Series D Financing 153
Direct Flow Medical Secures USD0.28 Million in Venture Funding 155
Coherex Medical Secures USD16.5 Million in Venture Funding 156
Aragon Pharma Raises US$42 Million In Series C Financing 157
Private Equity 158
Platinum Equity to Acquire LifeScan from Johnson & Johnson for USD2.1 Billion 158
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 159
Partnerships 160
Janssen Amends Licensing Agreement with Gilead for STR 160
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 161
RespireRx Pharma to Enter into Agreement Noramco 162
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 163
Noramco and SPI Pharma Enter into Agreement 164
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 165
Janssen Pharma to Enter into Agreement with Pharmstandard 166
Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development 167
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 168
Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research 169
Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University 170
Janssen Pharma Enters into Research Partnership with Beacon Discovery 171
Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala 172
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 173
Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome 174
Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute 175
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 176
Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 177
Genomic Health Enters into Research Agreement with Janssen Pharma 178
BioMed X Enters into Agreement with Janssen Research & Development 179
Cerveau Technologies Enters into Agreement with Janssen Pharma 180
Janssen Research & Development Enters into Agreement with U.S. Department of Health 181
Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 182
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 183
Proteros biostructures Enters into Research Agreement with Janssen Biotech 184
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 185
Idorsia and Janssen Biotech to Enter into option Agreement 186
Monash University Enters into Research Agreement with Janssen Biotech 187
Phagelux Enters into Agreement with Johnson & Johnson Consumer 188
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 189
PeptiDream Enters into Agreement with Janssen Pharma 190
Janssen Pharma Enters into Partnership with Premier 191
Renova Therapeutics Enters into Agreement with Janssen Pharma 192
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 193
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 194
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 195
Janssen Research & Development Enters into Agreement with ChemDiv 196
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 197
Enamine Expands Agreement with Actelion 198
Karolinska Institutet Partners with Johnson & Johnson Companies 199
Janssen Biotech Enters into Partnership with Bristol-Myers 200
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 201
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 202
Janssen Pharma Enters into Partnership with Bird Rock Bio 203
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 204
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 205
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 206
HitGen Enters into Agreement with Janssen Biotech 207
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 208
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 209
Philogen Enters Into Collaboration Agreement With Janssen Biotech 210
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 211
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 212
Amyris Enters into Research Agreement with Janssen Biotech 213
Janssen Research & Development Enters into Agreement with Genentech 214
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 215
DiamiR Enters into Research Agreement with Janssen Pharma 216
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 217
Janssen Biotech Enters into Agreement with HUB foundation 218
Janssen Pharma Enters into Agreement with University of Pennsylvania 219
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 220
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 221
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 222
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 223
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 224
Janssen Pharma Enters into Agreement with University of California, San Diego 225
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 226
Johnson & Johnson Consumer Enters into Agreement with BioMed X 227
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 228
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 229
Janssen Biotech Enters into Agreement with Eureka Therapeutics 230
Intrexon Enters into Research Agreement with Janssen Pharma 231
Cypralis Enters into Research Agreement with Janssen Pharma 232
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 233
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 234
SynAging Extends Agreement with Actelion Pharma 235
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 236
Nuevolution Enters into Discovery Agreement with Janssen Biotech 237
enGene Enters into Agreement with Janssen Biotech 238
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 239
BlinkBio Enters into Discovery Agreement with Janssen Pharma 240
UbiVac Enters into Agreement with Janssen Biotech 241
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 242
Nextera Enters into Research Agreement with Janssen Biotech 243
Handok Enters into Agreement with Actelion Pharmaceuticals 244
Actelion Forms Joint Venture with Max Planck Society 245
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 246
Janssen Cilag Enters into Agreement with UniQuest 247
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 248
Janssen Biotech Enters into Research Agreement with Emulate 249
Johnson & Johnson Innovation Partners with Lead Discovery Center 250
NeurOp Enters into Research Agreement with Janssen Pharma 251
AC Immune Enters into Research Agreement with Janssen Pharma 252
X-Chem Expands Agreement with Janssen Biotech 253
Vectura Enters into Development and License Agreement with Janssen Biotech 254
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 255
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 256
Atreca Enters into Research Agreement with Janssen Biotech 257
Vaccinex Enters into Research Agreement with Janssen Research & Development 258
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 259
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 260
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 261
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 262
Alector Enters Into Research Agreement With Janssen Pharma 263
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 264
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 265
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 266
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 267
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 268
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 269
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 270
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 271
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 272
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 273
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 274
ex scientia Enters into Agreement with Janssen Research & Development 276
Mellitech Enters into Agreement with Janssen Pharma 277
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 278
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 279
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 280
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 281
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 282
Open Monoclonal Expands Agreement with CNA Development 283
Beactica Enters Into Research Agreement With Janssen Research & Development 284
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 285
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 286
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 287
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 288
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 289
Dendright Enters Into Research Agreement With Janssen-Cilag 290
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 291
Licensing Agreements 292
Macleods Pharma May Enter into Licensing Agreement with Johnson & Johnson 292
Janssen Biotech Enters into Licensing Agreement with Nuevolution 293
Janssen Biotech Enters into Licensing Agreement with Legend Biotech 294
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 295
Janssen Biotech Enters into Licensing Agreement with Zymeworks 296
Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 297
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 298
Janssen Pharma Enters into Licensing Agreement with St Vincents Institute of Medical Research 300
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 301
Pulmatrix Enters into Licensing Agreement with RespiVert 302
Janssen Biotech Enters into Licensing Agreement with Trianni 303
Janssen Biotech Enters into Licensing Agreement with Ablexis 304
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 305
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 307
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 308
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 309
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 310
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 311
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 312
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 313
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 314
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 315
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 316
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 317
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 318
Janssen Biotech Enters into Licensing agreement with Tesaro 319
ViaCyte Enters into Licensing Agreement with Janssen Biotech 320
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 321
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 322
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 323
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 324
Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 325
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 326
Poseida Therapeutics Enters into Licensing Agreement with Janssen 327
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 328
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 329
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 330
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 331
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 332
AC Immune Enters into Licensing Agreement with Janssen Pharma 333
Janssen Expands Licensing Agreement with Gilead 334
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 335
Kura Oncology Amends Licensing Agreement with Janssen Pharma 336
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 338
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 339
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 341
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 342
BeneVir Biopharm Enters into Licensing Agreement with New York University 343
AB-Biotics Enters into Licensing Agreement with Cilag 344
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 345
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 346
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 347
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 349
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 350
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 351
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 352
Janssen Pharma Enters into Licensing Agreement with BiocerOX 354
Orion Enters Into Licensing Agreement With Janssen Pharma 355
CSL Enters Into Licensing Agreement With Janssen For CSL-362 356
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 357
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 358
XO1 Enters into Licensing Agreement with Cambridge Enterprise 359
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 360
Amunix Expands Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 361
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 362
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 363
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 364
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 366
Shionogi Enters Into Licensing Agreement With Janssen Pharma 367
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 368
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 370
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 371
Depomed Enters Into Licensing Agreement With Janssen Pharma 373
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 374
Genmab Expands Licensing Agreement With Janssen Biotech 375
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 376
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 378
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 379
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 380
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 381
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 382
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 383
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 384
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 385
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 386
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 387
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 388
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 390
Intravacc Enters into Licensing Agreement with Crucell Holland 391
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 392
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 393
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 394
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 395
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 396
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 397
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 399
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 400
Equity Offering 401
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 401
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 403
Achillion Pharma to Raise Funds through Secondary Offering of Shares 404
Alligator Bioscience Raises USD252.8 Million in IPO 405
Tesaro Raises USD50 Million in Private Placement of Shares 407
Achillion Pharma Raises USD225 Million in Private Placement of Shares 408
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 410
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 412
MacroGenics Raises USD75 Million in Private Placement of Common Stock 414
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 416
Debt Offering 417
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 417
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 419
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 421
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 422
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 424
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 426
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 428
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 430
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 432
Asset Transactions 434
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 434
Kramer Labs Acquires Nizoral from Janssen Pharma 435
Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 436
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 437
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 438
Sinocare May Acquire Diabetes Care Business from Johnson & Johnson for up to USD4 Billion 439
HRA Pharma Acquires Compeed from Cilag 440
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 441
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 442
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 443
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 444
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 445
Vivus Acquires Topiramate Related Patents from Janssen Pharma 447
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 448
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 449
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 450
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 452
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 453
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 454
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 455
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 456
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 457
Acquisition 458
Janssen Biotech Acquires 76% stake in BeneVir Biopharm 458
Johnson & Johnson Acquires Actelion for USD30 Billion 459
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 461
Ethicon Acquires Torax Medical 463
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 464
Johnson & Johnson Consumer Acquires NeoStrata 465
DePuy Orthopaedics Acquires BioMedical Enterprises 466
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 467
Johnson and Johnson May Sell Noramco 468
Johnson & Johnson Acquires Novira Therapeutics 469
Biosense Webster Acquires Coherex Medical 470
Actelion Plans to Acquire ZS Pharma 471
Actelion Rejects Acquisition Offer from Shire 472
Janssen Pharma Acquires XO1 473
Valneva Acquires Crucell Sweden for USD54 Million 474
Tetraphase Pharma May Sell Itself 475
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 476
Cilag Acquires Covagen 478
Novartis Acquires CoStim Pharma 479
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 481
Johnson & Johnson Completes Acquisition Of Aragon Pharma For USD1 Billion 483
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 485
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 486
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 488
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 489
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 491
Janssen-Cilag Acquires CorImmun 492
Johnson & Johnson - Key Competitors 494
Johnson & Johnson - Key Employees 495
Johnson & Johnson - Locations And Subsidiaries 496
Head Office 496
Other Locations & Subsidiaries 496
Recent Developments 515
Financial Announcements 515
Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results 515
Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results 517
Oct 17, 2017: Johnson & Johnson Reports 2017 Third-Quarter Results 519
Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 521
Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 523
Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 525
Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 527
Corporate Communications 529
Jun 22, 2018: Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson 529
Jun 22, 2018: Johnson & Johnson Appoints Senior Leaders to Executive Committee 530
Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson 531
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 532
Legal and Regulatory 533
Apr 03, 2018: JNJ DEADLINE NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors of Important April 9, 2018 Deadline in Class Action - JNJ 533
Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer 534
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 535
Jan 05, 2017: Missouri Court Denies J&J Request to Delay Talc-Related Cancer Trials 536
Government and Public Interest 537
Jun 05, 2018: Johnson & Johnson Announces Progress Toward Health for Humanity Goals 537
Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 538
Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 539
Product News 540
09/29/2017: Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership 540
08/02/2017: FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis 542
05/30/2017: Cerecor to present at the American Society for Clinical Psychopharmacology Conference 543
05/22/2018: Global Alzheimers Platform Foundation Comments On Janssens Termination of The EARLY Study of Atabecestat 544
03/30/2017: Janssen Discontinues Development of Flubendazole Formulation to Treat Onchocerciasis 545
03/07/2017: Actelion is Granted Marketing Authorization by the European Commission for Ledaga (Chlormethine Gel) for the Treatment of MF-CTCL 546
Product Approvals 547
Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate 547
Clinical Trials 548
Jun 07, 2018: Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab 548
Dec 28, 2017: Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression 549
Oct 17, 2017: Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer 551
Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder 552
Jun 14, 2017: Janssen Presents Long Term Ph

List Of Tables

List of Tables
Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Johnson & Johnson, Deals By Therapy Area, 2012 to YTD 2018 23
Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 25
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27
Janssen Pharma Acquires CERC-501 from Cerecor 59
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 60
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 61
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 62
Evolve BioSystems Raises USD40 Million in Series C Financing 63
Syndesi Therapeutics Raises USD21 Million in Series A Financing 65
On Target Labs Raises USD40 Million in Series B Financing 67
BeneVir Biopharm Raises USD2 Million in Venture Financing 68
Fusion Pharma Raises Additional USD17 Million in Series A Financing 69
XW Labs Raises USD17.5 Million in Series B Financing 71
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 72
E-scape Bio Raises Additional USD8 Million in Series A Financing 73
DayTwo Secures USD12 Million in Series A Funding 74
DayTwo Raises USD12 Million in Series A Financing 75
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 76
Biomx Raises USD24 Million in Series A Venture Financing 77
Pulmocide Raises USD30.4 Million in Series B Financing 79
Fusion Pharma Raises USD19 Million in Series A Financing 81
SuperX Raises USD11 Million in Series A Financing 82
Caelus Health Raises USD2.7 Million in Series A Financing 83
ApoGen Biotech Raises USD7 Million in Series A Financing 84
ReVision Optics Raises USD32 Million in Venture Financing 85
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 87
BeneVir Biopharm Raises USD3 Million in Venture Financing 88
V-Wave Raises USD28 Million in Venture Financing 89
Lodo Therapeutics Raises USD17 Million in Series A Financing 90
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 92
Petra Pharma Raises USD48 Million in Series A Financing 93
Protekt Therapeutics Raises More Than USD2 Million in Financing 95
Navitor Pharma Raises USD33 Million in Series B Financing 96
First Aid Shot Therapy Raises USD24 Million in Series C Financing 98
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 99
Asceneuron Raises USD30.6 Million in Series A Financing 100
Merus Raises USD46.4 Million in First Tranche of Series C Financing 102
E-scape Bio Raises USD55 Million in Series A Financing 104
Alligator Bioscience to Raise Funds through Venture Financing 105
Protagonist Therapeutics Raises USD40 Million in Series C Financing 106
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 108
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 110
BeneVir Biopharm Raises Funds through Series A Financing 111
Tetra Discovery Raises Funds through Venture Financing 112
XW Labs Raises USD5.5 Million in Series A Financing 113
Inivata Raises USD6.5 Million in Venture Financing 114
Inviata Raises USD6.5 Million in Venture Financing 115
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 116
Ascelegen Therapeutics Raises Funds through Venture Financing 117
Padlock Therapeutics Raises Funds through Series A Financing 118
Navitor Pharma Raises USD24 Million in Series A Financing 119
Aduro BioTech Raises USD55 Million in Series C Financing 121
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 122
Assembly Pharma Raises Funds Through Seed Financing 123
Alios BioPharma Raises US$41 Million In Series B Venture Financing 124
Covagen Raises US$50.3 Million In Series B Financing 125
Novira Therapeutics Raises US$28 Million In Series A Financing 127
SutroVax Raises Funds Through Initial Financing Round 129
TopiVert Raises USD28 Million in Venture Financing 130
TopiVert Raises US$7.4 Million In Venture Financing 131
Pulmocide Raises US$27.4 Million In Series A Financing 133
Biocartis Raises US$40.5 Million In Series E Financing 135
Merus Raises US$42 Million In Extended Series B Financing 137
Rodin Therapeutics Raises Funds Through Seed Financing 139
Vedanta Biosciences Raises Funds Through Venture Financing 140
XO1 Raises USD11 Million in Venture Financing 141
X01 Raises US$11 Million In Series A Financing 142
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 143
Novira Therapeutics Secures USD25 Million in Venture Funding 144
Aquinox Pharma Raises US$18 Million In Series C Financing 145
Biocartis Raises US$44.7 Million In Series D Financing 146
Genocea Biosciences Raises US$30 Million In Series C Financing 148
Aragon Pharma Raises US$50 Million In Series D Financing 150
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 151
Celladon Raises Additional US$10 Million In Series D Financing 153
Direct Flow Medical Secures USD0.28 Million in Venture Funding 155
Coherex Medical Secures USD16.5 Million in Venture Funding 156
Aragon Pharma Raises US$42 Million In Series C Financing 157
Platinum Equity to Acquire LifeScan from Johnson & Johnson for USD2.1 Billion 158
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 159
Janssen Amends Licensing Agreement with Gilead for STR 160
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 161
RespireRx Pharma to Enter into Agreement Noramco 162
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 163
Noramco and SPI Pharma Enter into Agreement 164
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 165
Janssen Pharma to Enter into Agreement with Pharmstandard 166
Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development 167
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 168
Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research 169
Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University 170
Janssen Pharma Enters into Research Partnership with Beacon Discovery 171
Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala 172
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 173
Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome 174
Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute 175
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 176
Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 177
Genomic Health Enters into Research Agreement with Janssen Pharma 178
BioMed X Enters into Agreement with Janssen Research & Development 179
Cerveau Technologies Enters into Agreement with Janssen Pharma 180
Janssen Research & Development Enters into Agreement with U.S. Department of Health 181
Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 182
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 183
Proteros biostructures Enters into Research Agreement with Janssen Biotech 184
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 185
Idorsia and Janssen Biotech to Enter into option Agreement 186
Monash University Enters into Research Agreement with Janssen Biotech 187
Phagelux Enters into Agreement with Johnson & Johnson Consumer 188
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 189
PeptiDream Enters into Agreement with Janssen Pharma 190
Janssen Pharma Enters into Partnership with Premier 191
Renova Therapeutics Enters into Agreement with Janssen Pharma 192
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 193
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 194
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 195
Janssen Research & Development Enters into Agreement with ChemDiv 196
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 197
Enamine Expands Agreement with Actelion 198
Karolinska Institutet Partners with Johnson & Johnson Companies 199
Janssen Biotech Enters into Partnership with Bristol-Myers 200
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 201
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 202
Janssen Pharma Enters into Partnership with Bird Rock Bio 203
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 204
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 205
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 206
HitGen Enters into Agreement with Janssen Biotech 207
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 208
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 209
Philogen Enters Into Collaboration Agreement With Janssen Biotech 210
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 211
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 212
Amyris Enters into Research Agreement with Janssen Biotech 213
Janssen Research & Development Enters into Agreement with Genentech 214
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 215
DiamiR Enters into Research Agreement with Janssen Pharma 216
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 217
Janssen Biotech Enters into Agreement with HUB foundation 218
Janssen Pharma Enters into Agreement with University of Pennsylvania 219
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 220
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 221
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 222
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 223
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 224
Janssen Pharma Enters into Agreement with University of California, San Diego 225
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 226
Johnson & Johnson Consumer Enters into Agreement with BioMed X 227
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 228
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 229
Janssen Biotech Enters into Agreement with Eureka Therapeutics 230
Intrexon Enters into Research Agreement with Janssen Pharma 231
Cypralis Enters into Research Agreement with Janssen Pharma 232
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 233
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 234
SynAging Extends Agreement with Actelion Pharma 235
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 236
Nuevolution Enters into Discovery Agreement with Janssen Biotech 237
enGene Enters into Agreement with Janssen Biotech 238
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 239
BlinkBio Enters into Discovery Agreement with Janssen Pharma 240
UbiVac Enters into Agreement with Janssen Biotech 241
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 242
Nextera Enters into Research Agreement with Janssen Biotech 243
Handok Enters into Agreement with Actelion Pharmaceuticals 244
Actelion Forms Joint Venture with Max Planck Society 245
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 246
Janssen Cilag Enters into Agreement with UniQuest 247
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 248
Janssen Biotech Enters into Research Agreement with Emulate 249
Johnson & Johnson Innovation Partners with Lead Discovery Center 250
NeurOp Enters into Research Agreement with Janssen Pharma 251
AC Immune Enters into Research Agreement with Janssen Pharma 252
X-Chem Expands Agreement with Janssen Biotech 253
Vectura Enters into Development and License Agreement with Janssen Biotech 254
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 255
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 256
Atreca Enters into Research Agreement with Janssen Biotech 257
Vaccinex Enters into Research Agreement with Janssen Research & Development 258
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 259
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 260
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 261
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 262
Alector Enters Into Research Agreement With Janssen Pharma 263
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 264
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 265
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 266
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 267
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 268
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 269
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 270
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 271
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 272
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 273
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 274
ex scientia Enters into Agreement with Janssen Research & Development 276
Mellitech Enters into Agreement with Janssen Pharma 277
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 278
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 279
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 280
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 281
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 282
Open Monoclonal Expands Agreement with CNA Development 283
Beactica Enters Into Research Agreement With Janssen Research & Development 284
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 285
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 286
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 287
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 288
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 289
Dendright Enters Into Research Agreement With Janssen-Cilag 290
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 291
Macleods Pharma May Enter into Licensing Agreement with Johnson & Johnson 292
Janssen Biotech Enters into Licensing Agreement with Nuevolution 293
Janssen Biotech Enters into Licensing Agreement with Legend Biotech 294
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 295
Janssen Biotech Enters into Licensing Agreement with Zymeworks 296
Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 297
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 298
Janssen Pharma Enters into Licensing Agreement with St Vincents Institute of Medical Research 300
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 301
Pulmatrix Enters into Licensing Agreement with RespiVert 302
Janssen Biotech Enters into Licensing Agreement with Trianni 303
Janssen Biotech Enters into Licensing Agreement with Ablexis 304
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 305
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 307
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 308
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 309
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 310
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 311
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 312
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 313
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 314
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 315
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 316
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 317
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 318
Janssen Biotech Enters into Licensing agreement with Tesaro 319
ViaCyte Enters into Licensing Agreement with Janssen Biotech 320
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 321
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 322
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 323
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 324
Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 325
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 326
Poseida Therapeutics Enters into Licensing Agreement with Janssen 327
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 328
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 329
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 330
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 331
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 332
AC Immune Enters into Licensing Agreement with Janssen Pharma 333
Janssen Expands Licensing Agreement with Gilead 334
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 335
Kura Oncology Amends Licensing Agreement with Janssen Pharma 336
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 338
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 339
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 341
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 342
BeneVir Biopharm Enters into Licensing Agreement with New York University 343
AB-Biotics Enters into Licensing Agreement with Cilag 344
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 345
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 346
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 347
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 349
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 350
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 351
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 352
Janssen Pharma Enters into Licensing Agreement with BiocerOX 354
Orion Enters Into Licensing Agreement With Janssen Pharma 355
CSL Enters Into Licensing Agreement With Janssen For CSL-362 356
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 357
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 358
XO1 Enters into Licensing Agreement with Cambridge Enterprise 359
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 360
Amunix Expands Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 361
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 362
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 363
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 364
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 366
Shionogi Enters Into Licensing Agreement With Janssen Pharma 367
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 368
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 370
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 371
Depomed Enters Into Licensing Agreement With Janssen Pharma 373
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 374
Genmab Expands Licensing Agreement With Janssen Biotech 375
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 376
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 378
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 379
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 380
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 381
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 382
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 383
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 384
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 385
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 386
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 387
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 388
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 390
Intravacc Enters into Licensing Agreement with Crucell Holland 391
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 392
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 393
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 394
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 395
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 396
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 397
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 399
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 400
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 401
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 403
Achillion Pharma to Raise Funds through Secondary Offering of Shares 404
Alligator Bioscience Raises USD252.8 Million in IPO 405
Tesaro Raises USD50 Million in Private Placement of Shares 407
Achillion Pharma Raises USD225 Million in Private Placement of Shares 408
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 410
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 412
MacroGenics Raises USD75 Million in Private Placement of Common Stock 414
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 416
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 417
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 419
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 421
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 422
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 424
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 426
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 428
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 430
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 432
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 434
Kramer Labs Acquires Nizoral from Janssen Pharma 435
Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 436
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 437
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 438
Sinocare May Acquire Diabetes Care Business from Johnson & Johnson for up to USD4 Billion 439
HRA Pharma Acquires Compeed from Cilag 440
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 441
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 442
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 443
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 444
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 445
Vivus Acquires Topiramate Related Patents from Janssen Pharma 447
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 448
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 449
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 450
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 452
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 453
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 454
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 455
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 456
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 457
Janssen Biotech Acquires 76% stake in BeneVir Biopharm 458
Johnson & Johnson Acquires Actelion for USD30 Billion 459
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 461
Ethicon Acquires Torax Medical 463
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 464
Johnson & Johnson Consumer Acquires NeoStrata 465
DePuy Orthopaedics Acquires BioMedical Enterprises 466
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 467
Johnson and Johnson May Sell Noramco 468
Johnson & Johnson Acquires Novira Therapeutics 469
Biosense Webster Acquires Coherex Medical 470
Actelion Plans to Acquire ZS Pharma 471
Actelion Rejects Acquisition Offer from Shire 472
Janssen Pharma Acquires XO1 473
Valneva Acquires Crucell Sweden for USD54 Million 474
Tetraphase Pharma May Sell Itself 475
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 476
Cilag Acquires Covagen 478
Novartis Acquires CoStim Pharma 479
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 481
Johnson & Johnson Completes Acquisition Of Aragon Pharma For USD1 Billion 483
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 485
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 486
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 488
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 489
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 491
Janssen-Cilag Acquires CorImmun 492
Johnson & Johnson, Key Competitors 494
Johnson & Johnson, Key Employees 495
Johnson & Johnson, Subsidiaries 496

List Of Figures

List of Figures
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 25

Johnson and Johnson (JNJ) - Medical Equipment - Deals and Alliances Profile

Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological

USD 250View Report

Johnson Matthey Plc (JMAT) - Financial and Strategic SWOT Analysis Review

Johnson Matthey Plc (JMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125View Report

Johnson and Johnson (JNJ) - Medical Equipment - Deals and Alliances Profile

Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological

USD 250View Report

Johnson and Johnson - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Johnson & Johnson - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Johnson & Johnson Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :569
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube